Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Adjuvant Apatinib vs. TACE in HCC
NCT03511703Phase 2
Key facts
- Status
- Unknown
- Start
- May 2018
- Primary completion
- Dec 2018
- Sponsor
- Guangxi Medical University
- Modality
- Small Molecules
- Drugs
- Rivoceranib
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Guangxi Medical University. Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Apatinib
Experimental arm receiving Apatinib
TACE
Active control arm receiving Transarterial Chemoembolization (TACE)
03
Who it enrols
Patients with HCC diagnosed by histopathology or cytology, with residual disease or high risk features (AFP not normal 2 months post-op, residual lesions, vascular invasion, >3 tumors) after operation. Child-Pugh A or B (<=7).
04
Endpoints
Primary
Overall Survival
Beyond the preview
Go deeper on NCT03511703.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511703.